News
Issued by Adagene Inc., not Incyte Corporation
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
April 2, 2026 · Published on GlobeNewswire
It isn’t one of Incyte Corporation’s news releases, so 6ix doesn’t show it on Incyte Corporation’s page or send it as an alert.